baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

KYOWA KIRIN CO. LTD./ JP3256000005 /

2024-08-15 8:01:08 AM	Chg. -0.200	Volume	Bid8:21:05 AM	Ask8:21:05 AM	Market Capitalization	Dividend Y.	P/E Ratio
18.600EUR	-1.06%	- Turnover: -	18.500Bid Size: 133	19.100Ask Size: 133	10.26 bill.EUR	-	-

GlobeNewswire 06-28 Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Heal...

GlobeNewswire 06-28 Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on Intern...

GlobeNewswire 06-13 Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

GlobeNewswire 05-30 Ardelyx, Inc. Reports Employment Inducement Grants

GlobeNewswire 05-23 Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first pote...

GlobeNewswire 05-22 Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference

GlobeNewswire 05-21 Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapano...

GlobeNewswire 05-16 Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)

GlobeNewswire 05-15 Lantheus Announces Executive Appointments to Accelerate Innovation

GlobeNewswire 05-14 Ardelyx, Inc. Reports Employment Inducement Grants

GlobeNewswire 05-08 Pharming Group reports first quarter 2024 financial results and provides business update

GlobeNewswire 05-07 Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Ir...

GlobeNewswire 05-07 Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

GlobeNewswire 05-03 Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024...

GlobeNewswire 05-02 Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-02 Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-02 BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-01 Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Ch...

GlobeNewswire 04-23 AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval...

GlobeNewswire 04-18 Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024

GlobeNewswire 04-10 Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as Pr...

GlobeNewswire 03-28 Ardelyx, Inc. Reports Employment Inducement Grants

GlobeNewswire 03-25 Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...

GlobeNewswire 03-20 Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Ap...

GlobeNewswire 03-18 Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy ...

KYOWA KIRIN CO. LTD./ JP3256000005 /

If you wish to receive reply to your feedback, please provide your email address.